AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...